Ignet

Gene Pair: BRCA2, MSH2

Related Sentences

#	PMID	Sentence
1	33426465	Patients (N=37 349) had RS results of whom 714 had <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, or Lynch syndrome (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>) PVs.
2	33426465	For women aged 50 years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (≥26) with <i>BRCA1</i> (71.7% vs 14.4% with none; <i>P</i> <.001), <i>PALB2</i> (37.1%; <i>P</i> = .001), and <i>BRCA2</i> (44.3%; <i>P</i> < .001) PVs.
3	33426465	PVs in <i>BRCA1</i>, but not <i>BRCA2</i>, <i>PALB2</i>, <i>ATM</i>, <i>CHEK2</i>, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (<i>P</i> < .001).
4	33484353	Mutation analysis of MLH1, MSH2, BRCA1 and BRCA2 genes showed pathogenic variants in 17/40 (42.5%) patients.
5	35293552	The following genes were selected: BRCA1, PALB2, RAD51C, BRCA2, ATM, FANCA, MSH2, XPA, ERCC1, PARP1, and SNM1.
6	35293552	The DNA expression of 2 genes assessed in pre-NACT biopsies (PALB2 and ERCC1) was lower in pCR than in non-pCR patients (P=0.005 and P=0.009, respectively).
7	35293552	The genes BRCA2 (P=0.009), ATM (P=0.004), FANCA (P=0.001), and PARP1 (P=0.011) showed a lower expression in post-NACT residual tumor samples (n=32) than in pre-NACT biopsy samples (n=98).
8	35293552	The expression of 2 genes (PALB2 and ERCC1) was lower in pCR patients.